EuroPCR 2018 | DESSOLV III: Bioabsorbable vs. Durable Polymer at 2 Years

Most drug-eluting stents are coated by a polymer that is used to contain the antiproliferative drug. Once the drug is released, the polymer remains in place and its presence has been associated with inflammation, restenosis, and neoatherosclerosis. The MiStent device features a polymer that becomes bioabsorbable once the drug has been released, which could, theoretically, reduce the inflammatory response of the treated segment. MiStent was designed to meet three requirements: a thin-strut platform, a bioabsorbable polymer that disappears from the vessel in 3 months, and a drug whose effect remains for 9 months. The last characteristic is what makes this stent stand out among other bioresorbable-polymer stents in which the effect of the drug vanishes along with the polymer.

EuroPCR 2018 | DESSOLV III: polímero bioabsorbible vs durable a 2 añosThe study included 1398 patients from 20 sites and 4 countries, 60% of whom were included in a setting of acute coronary syndrome. Subjects with diabetes, left main lesions, restenosis, or lesions in vein grafts were also eligible (a typical all-comers population). Stable patients received dual antiplatelet therapy for 6 months, while acute patients received it for a year.

 

The primary endpoint was a composite of cardiac death, acute myocardial infarction, and target-vessel revascularization.


Read also: LEADERS FREE: Complex Angioplasty in Patients with High Risk for Bleeding.


At 2 years, there was no statistically significant difference in the rate of clinical events driven by the device (8.6% for MiStent vs. 8.7% for Xience; p = 0.958).

 

There was a trend towards a lower risk for revascularization with the new device, although the difference was not significant (5.4% vs. 4.6%; p = 0.44).


Read also: EuroPCR 2018 | SPYRAL HTN-ON MED: Renal Denervation Comes Back to Life.


In the final analysis at three years, we will see if there are new differences that can be attributed to the disappearing polymer.

 

Original title: A Randomised Comparison of a Sirolimus-Eluting Bioabsorbable Polymer-Coated Stent vs. an Everolimus-Eluting Durable Polymer Stent in an All-Comer Population – 24-Month Update.

Presenter: W. Wijns.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

TCT 2024 | Use of Drug-Coated Balloons for Side Branch Treatment in Provisional Stenting

In some cases, treating coronary bifurcations with provisional stenting requires side branch stenting, which may lead to suboptimal outcomes. Drug-coated balloons (DCBs) have emerged...

TCT 2024 | Use of Artificial Intelligence for Patients with Suspected Coronary Artery Disease

The current approach to chest pain mainly focuses on symptom characteristics, conducting functional tests for ischemia assessment. However, several randomized clinical trials have shown...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...